Baseline cytogenetic studies at diagnosis remain the single most important determinant of
outcome in patients with acute myeloid leukemia (AML). However, the prognostic role of the …

Karyotypic analysis at time of diagnosis has an important value in determining initial
response to treatment, remission duration and overall survival (OS) in acute myeloid …

Risk stratification is important to identify patients with acute myelogenous leukemia (AML)
who might benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) in …

Outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
nonremission acute myeloid leukemia (AML) are dismal [2-year overall survival (OS): 20 …

Background Despite significant therapeutic progress, many patients with acute leukemia die
from deteriorating disease after relapse. Relapse of acute leukemia has repeatedly been …

To determine the association of somatic mutations in acute myeloid leukemia (AML) with risk
of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT), we …

Objectives The purpose of this study was to evaluate the predictive capacity of the European
LeukemiaNet (ELN) classification of genetic risk in patients with acute myeloid leukaemia …

Several gene mutations have been shown to provide clinical implications in patients with
acute myeloid leukemia (AML). However, the prognostic impact of gene mutations in the …

Disease relapse is the major cause of treatment failure after allogeneic stem cell
transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated …

We evaluated the prognostic significance of a modified European LeukemiaNet (ELN)
classification for patients with acute myelogenous leukemia (AML) undergoing …